Treatment Individualization in Colorectal Cancer by Robin M. J. M. van Geel et al.
THERAPEUTIC APPROACHES TO METASTATIC COLORECTAL CANCERS (LVECCHIONE, SECTION EDITOR)
Treatment Individualization in Colorectal Cancer
Robin M. J. M. van Geel1 & Jos H. Beijnen1,2,4 & René Bernards3 & Jan H.M. Schellens1,4
Published online: 26 August 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Colorectal cancer has been characterized as a ge-
netically heterogeneous disease, with a large diversity in mo-
lecular pathogenesis resulting in differential responses to ther-
apy. However, the currently available validated biomarkers
KRAS, BRAF, and microsatellite instability do not sufficient-
ly cover this extensive heterogeneity and are therefore not
suitable to successfully guide personalized treatment. Recent
studies have focused on novel targets and rationally designed
combination strategies. Furthermore, a more comprehensive
analysis of the underlying biology of the disease revealed
distinct phenotypic differences within subgroups of patients
harboring the same genetic driver mutation with both prog-
nostic and predictive relevance. Accordingly, patient stratifi-
cation based on molecular intrinsic subtypes rather than on
single gene aberrations holds promise to improve the clinical
outcome of patients with colorectal cancer.
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Introduction
Colorectal cancer (CRC) is one of the most prevalent cancers
and a leading cause of cancer mortality worldwide [1]. In an
effort to better understand the biologic hallmarks of the dis-
ease, CRC has undergone extensive molecular characteriza-
tion in recent years, which revealed important oncogenes (e.g.,
KRAS, BRAF, PIK3CA), tumor suppressor genes (e.g., APC,
TP53, PTEN) and signaling pathways that are critical for the
development, survival, and progression of CRC cells. These
genes are involved inmajor signaling pathways that have been
linked to cancer, including the WNT/β-catenin, mitogen-
activated protein kinase (MAPK), transforming growth factor
beta (TGF-β) and phosphoinositide 3-kinase (PI3K) pathways
(Fig. 1) [2]. Consequently, targeted agents against a number of
druggable genomic aberrations were developed. However, pa-
tients who are characterized based on these molecular markers
still show remarkable variability in terms of prognosis and
response to therapy [3]. Therefore, many studies have ad-
dressed further subclassification of CRC, focusing on epige-
netic factors and gene expression profiles. Herein we outline
recent advances in our understanding of the underlying biol-
ogy of CRC, and we address the potential clinical implications
of this knowledge in order to optimize treatment individuali-
zation for patients with CRC.
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Single Genetic Aberration Driven Treatment
In the past decade, in search of better biomarkers in the met-
astatic setting of CRC (mCRC), a wide range of genetic alter-
ations was found to be associated with cancer. Only a small
percentage of these mutations actually drive the development
and progression of malignant cells and may therefore have
clinical implications [4, 5]. Mutations in the RAS genes
(KRAS, HRAS, and NRAS), present in approximately 50 %
of all patients with CRC, result in hyper activation of RAS
proteins and their corresponding downstream pathways such
as the MAPK pathway, thereby stimulating the development
and progression of malignant tumors [6]. As RAS mutations
predict resistance to anti-EGFR monoclonal antibodies
(mAbs) cetuximab and panitumumab, patients with RAS mu-
tant disease should be excluded from treatment with these
drugs [7–11]. However, a large part of the RAS wild-type
patients still do not respond to cetuximab or panitumumab.
Further refinement in the molecular analysis of patients who
are considered for treatment with anti-EGFR mAbs is there-
fore needed. Others, including Saridaki et al. in this issue,
describe potential additional biomarkers and the uncertainties
that remain to be solved. In short, mounting evidence in the
literature supports the notion that resistance to anti-EGFR
mAbs can be explained by genetic alterations in the MAPK
and PI3K pathways [10, 12–14]. Although this evidence is
largely based on retrospective analyses, which are often
underpowered to address the impact of less common gene
mutations (e.g., NRAS, non-codon 12 KRAS, BRAF,
PIK3CA), there were trends of unresponsiveness upon
cetuximab and panitumumab treatment. On the other hand,
based on ameta-analysis of seven randomized controlled trials,
Rowland et al. concluded that there is insufficient data to jus-
tify the exclusion of EGFR inhibitor therapy for patients with
BRAFm mCRC [15]. Nevertheless, only 15 % of all patients
with mCRC, who represent the quadruple wild-type (KRAS/
NRAS/BRAF/PIK3CA) group, is thought to respond to anti-
EGFR therapy [13, 16]. Therefore, effective alternatives for
patients that do harbor mutations in these genes are needed.
MAPK Pathway
Since the paradigm shift, changing from a histology-directed
treatment approach to a genome-driven strategy, a large num-
ber of clinical trials investigated targeted agents against spe-
cific molecular anomalies. Patients were stratified according
to their tumors’KRAS, BRAF,NRAS, PIK3CA, orPTEN status
to receive a matched targeted agent. However, none of these
strategies has obtained proof of principle in patients with CRC
[17–21]. Clearly, targeting a single mutated gene or activated
protein in CRC does not yield the desired clinical benefit. In
the meantime, preclinical research provided more insight into
the dynamic interactions between different signaling path-
ways and emphasized that single kinase protein inhibition is
way too simplistic as it ignores the complexity of feedback
escape mechanisms and cross-talk between pathways. An im-
pressive example is the contradictory efficacy of BRAF inhib-
itors in patients with melanoma versus patients with CRC.
Selective BRAF inhibitors such as vemurafenib and
dabrafenib have shown high objective response rates of about
50 % in patients with BRAF(V600E) mutated (BRAFm) mel-
anoma [22, 23]. Combinations of these small molecules with
MEK inhibitors like cobimetinib or trametinib further im-
proved the rate of response to over 65 % and yielded a signif-
icant improvement in both progression-free survival and over-
all survival [24, 25]. In contrast, CRC patients with the iden-
tical causative BRAF mutation appeared unresponsive to
BRAF inhibitors either as single agent or in combination with
a MEK inhibitor as indicated by response rates of less than
5 % [20, 21]. Prahallad and colleagues elucidated the mecha-
nism underlying this intrinsic unresponsiveness. Using an
RNA interference-based genetic screen, they searched for ki-
nase proteins, which upon suppression synergize with BRAF
inhibition in BRAFm CRC cells. EGFR came out as the most
potent synergy partner. Mechanistically, a feedback activation
of EGFR was identified upon BRAF inhibition in BRAFm
CRC supporting persistent tumor cell proliferation through
reactivation of the MAPK and PI3K pathways. Combined
BRAF and EGFR inhibition caused a strong synergistic effect
Fig. 1 Simplified schematic overview of the MAPK and PI3K signaling
pathway
336 Curr Colorectal Cancer Rep (2015) 11:335–344
in vitro and in xenograft models and resulted in complete
inhibition of tumor growth [26••]. An independent research
group reported similar results, BRAF inhibition in BRAFm
CRC triggered an EGFR-mediated rebound activation of the
MAPK pathway, which can be blocked by concomitant ad-
ministration of an anti-EGFR targeted agent [27••]. This re-
search supports clinical evaluation of combined BRAF and
EGFR inhibition in patients with BRAFmCRC, and a number
of ongoing clinical studies already have obtained clinical
proof of principle. A phase I study investigating BRAF inhib-
itor encorafenib (LGX818) combined with cetuximab, either
with or without PI3K inhibitor alpelisib (BYL719), demon-
strated favorable toxicity profiles of both the dual and triple
combination with objective response rates of 30% and disease
control rates of 80 and 90 %, respectively, in patients with
pretreated advanced BRAFm CRC [28]. Comparable clinical
activity was obtained in a second phase I study in which the
combination of BRAF inhibitor dabrafenib, EGFR inhibitor
panitumumab, and MEK inhibitor trametinib resulted in an
objective response rate of 26 % [29]. Interestingly,
vemurafenib plus cetuximab can also be safely combined with
irinotecan and preliminary results of the first 16 patients with
BRAFmmCRC revealed a 35% response rate [30]. Given the
particularly poor prognosis of patients with metastatic
BRAFm CRC and the limited anti-tumor activity of standard
treatment regimens in this subset of patients, new treatment
options are needed [31]. Although larger phase II/III trials are
necessary to confirm the promising initial results, combined
BRAF and EGFR inhibition is likely to improve standard of
care for BRAFm mCRC.
A second example of the dynamic biology of CRC con-
cerns KRAS mutant (KRASm) disease. Despite extensive in-
vestigation, direct pharmacological inhibition of the KRAS
protein remains difficult [32]. As an alternative, kinase pro-
teins downstream of KRAS such as MEK were investigated
but the anti-tumor activity was disappointing [33]. Upon the
recognition that PI3K pathway activation due to coexisting
genetic alterations or feedback upregulation may cause resis-
tance against MEK inhibition, clinical studies focused on
combining MEK inhibitors with PI3K, AKT or mTOR inhib-
itors, but these did not yield satisfactory results either [34].
Recently, investigators applied the previously described ge-
netic screen to KRASm cells and found that HER3 knock-
down sensitizes these cells for MEK inhibition. HER3 recep-
tors are able to activate both the MAPK and PI3K pathway
after dimerization with other members of the HER receptor
family of which EGFR and HER2 are the most potent dimer-
ization partners. Interestingly, combining a MEK inhibitor
with an inhibitor of EGFR or HER2 did not result in synergy.
Only MEK inhibition combined with dual EGFR/HER2 in-
hibitors or pan-HER inhibitors such as dacomitinib and
afatinib, overcomes unresponsiveness of KRASm tumors
in vitro as well as in vivo [35]. Based on a similar genetic drug
screen, Corcoran et al. suggested another approach. They
found that knockdown of the anti-apoptotic BH3 family gene
BCL-XL was synergistic with MEK inhibition and targeting
BCL-XL with ABT-263 (navitoclax) combined with a MEK
inhibitor resulted in dramatic apoptosis in vitro and remark-
able in vivo tumor responses in KRASm xenografts [36].
Clinical studies investigating these combinations are under-
way (NCT02039336, NCT02230553, NCT02450656,
NCT02079740). Additionally, recent research provided new
hope for the development of drugs that directly bind and in-
hibit the mutated RAS protein, by exploiting a mutation-
specific approach [37, 38]. However, given the existing
cross-talk between signaling pathways via feedback mecha-
nisms, these novel therapeutic agents may urge for combina-
tion strategies as well. Furthermore, even if these investiga-
tional therapies provide benefit in the clinic, it seems likely,
given the heterogeneity of CRC, that only a subset of KRASm
and BRAFm patients will respond.
PI3K Pathway
Similar to the MAPK pathway, the PI3K pathway can be
activated by receptor tyrosine kinases, including EGFR family
members, platelet-derived growth-factor receptors (PDGFR)
and the insulin growth-factor-1 receptors. Mutations in
PIK3CA, the gene that codes for the p110α isoform of the
PI3K protein, are present in approximately 15 % of CRC
and are concentrated in two hot spots of the gene at exon 9
(60–65%) and exon 20 (20–25%) [10, 39]. Exon 9 mutations
affect the helical domain and cause gain of function indepen-
dent of dimerization with the p85 subunit of PI3K, but require
interaction with activated RAS. Exon 20 mutations on the
other hand result in gain of PI3K function independent of
activated RAS but highly rely on the interaction with p85
[40]. Therefore, these mutations might reflect two distinct
subtypes of PI3K that behave differently upon a given treat-
ment. Indeed, PIK3CA exon 9 mutations have been associated
with activating KRAS mutations in codons 12 and 13,
supporting the functional link between RAS signaling and
activation of the helical domain of PI3K [10, 39, 41]. In con-
trast, others describe an association between KRAS mutations
and PIK3CA mutations regardless of the exonic site [42].
These mechanistic differences may explain the discordant
findings regarding the detrimental effect ofPIK3CAmutations
on the efficacy of anti-EGFR treatment. Initial reports showed
an association between PIK3CA mutations and lack of re-
sponse to anti-EGFR mAbs, but these results were not con-
firmed by others, possibly due to the lower number of exon 20
mutations in the latter studies [13, 43–45]. Inhibition of the
PI3K pathway using small molecules targeting PI3K, mTOR,
or AKTwas recently investigated but has not yielded satisfac-
tory results in CRC patients with PI3K alterations [46]. In
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addition to PIK3CA mutations, loss of PTEN expression is a
second PI3K pathway component that has been associated
with resistance to EGFR inhibition [47–50]. However, the
effect of PIK3CA mutations and loss of PTEN on anti-
EGFR therapy seems relatively weak and alterations in the
PI3K pathway often co-occur with other important driver mu-
tations likeKRAS and BRAF, indicating that the PI3K pathway
plays a less critical role compared to the MAPK pathway in
unresponsiveness to EGFR inhibition in CRC and maybe
even in CRC in general [13, 51].
Taken together, so-called quadruple-negative (no muta-
tions in KRAS, NRAS, BRAF, PIK3CA) CRC is more likely
to respond to EGFR inhibitors treatment and for those patients
that do possess specific genetic mutations (BRAF and KRAS)
clinical studies with new combination strategies are ongoing.
However, presence of oncogenic mutations still do not fully
explain the extent of non-response to EGFR inhibition and
success stories with single gene mutation-directed therapy in
patients with CRC are limited [52].
In contrast to CRC, targeting single mutated genes in he-
matological malignancies yielded a number of breakthrough
therapies, such as BCR-ABL kinase inhibitor imatinib, and
later dasatinib and nilotinib for patients with Philadelphia
chromosome positive chronic myelogenous leukemia
[53–55]. A number of reasons may explain this remarkable
difference in success rate of targeting oncogenic drivers. First,
unlike hematological malignancies, most solid tumors, and
especially CRC, contain many genetic aberrations, which
could make these tumors less dependent on a single oncogenic
mutation. Moreover, this heterogeneity of CRC, in that it con-
tains not only a mixture of relatively indolent and aggressive
cells but also a mixture of molecularly different cell popula-
tions, makes it difficult to attack all these distinctive cells with
the same targeted agents. Killing the sensitive cells might offer
resistant cell populations the opportunity to expand and prog-
ress. Secondly, the affected signaling pathways often ‘com-
municate’ with each other, resulting in primary resistance
against a given targeted agent as described previously for
BRAFm and KRASm CRC. Thirdly, CRC behavior appears
largely dependent on the surrounding stromal context in
which the tumor exists [56, 57]. Therefore, treatment individ-
ualization for patients with CRC needs to take these features




Traditionally, early-stage CRC is classified based on tumor
stage in order to estimate prognosis and predict benefit of
adjuvant treatment. All patients with stage III or high-risk
stage II disease are offered adjuvant chemotherapy.
However, in a significant percentage of patients adjuvant che-
motherapy is ineffective. Better prognostic and predictive
markers are therefore needed to identify patients who are more
likely to benefit from adjuvant treatment [58]. Initial studies
described three molecularly distinct features in CRC, namely
microsatellite instability (MSI), chromosomal instability
(CIN), and the CpG island methylator phenotype (CIMP).
CIN is present in the vast majority (~85 %) of CRCs and is
characterized by alterations in the adenomatous polyposis coli
(APC) gene, a key component of the WNT pathway. MSI on
the other hand is detected in approximately 15 % of all early-
stage CRCs and displays a hypermutable phenotype caused
by a defective mismatch repair system (dMMR). In the clini-
cal setting, MSI may be used to genetically diagnose Lynch
syndrome, to estimate the prognosis of patients with CRC and
to predict the efficacy of chemotherapeutic agent 5-
fluorouracil (5-FU). Together with other studies, a large
meta-analysis with over 7000 patients demonstrated that stage
II or III colorectal tumors have a survival advantage if they
exhibit MSI rather than a stable microsatellite status (MSS) as
shown by the lower rates of tumor recurrence in MSI tumors
[59]. The predictive role of MSI or dMMR for treatment with
5-FU and other chemotherapeutic agents has been controver-
sial as several studies reported conflicting results. However,
large recent retrospective analyses of randomized clinical tri-
als confirmed that patients with dMMR should not be recom-
mended for adjuvant treatment with 5-FU due to lack of ben-
efit, but that this effect is limited to stage II patients [60–65]. In
addition to MSI status as identified by PCR amplification of
specific microsatellite repeats, Tian et al described a robust
gene expression signature that identifies patients with MSI
tumors and also a group of MSI-like patients who are not
recognized by traditional methods but have a phenotype sim-
ilar to MSI patients, including high mutation frequency, fre-
quent BRAF mutations, high tumoral thymidylate synthase
(TS) expression, and better prognosis [66]. As the unrespon-
siveness of MSI patients to adjuvant 5-FU therapy might be
related to higher TS expression,MSI-like patientsmight there-
fore present an additional population that have a lower likeli-
hood to benefit from 5-FU treatment [66, 67]. Furthermore,
Choueiri et al. described a potential role of TS and excision
repair cross-complementation group 1 (ERCC1) expression as
prognostic and predictive biomarkers in mCRC. Low TS ex-
pression was associated with significant longer overall surviv-
al and combined low expression of ERCC1, and TS was pre-
dictive of response in patients treated with FOLFOX [68].
To gain more insight into the heterogeneity of CRC, the
Cancer Genome Atlas Network (TCGA) conducted a compre-
hensive molecular characterization of CRC, including exome
sequencing, DNA copy number, promoter methylation, and
mRNA and miRNA expression analysis. Based on the muta-
tional rate, an arbitrary cutoff was used to distinguish two
separate groups, namely hypermutated (16 %) and non-
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hypermutated (84 %) tumor samples. The hypermutated
group consisted of tumors with MSI and CpG island methyl-
ator phenotype (CIMP), whereas the non-hypermutated tu-
mors had significantly more gene copy number alterations
and TP53 and KRAS mutations, indicating CIN. Analysis of
the specific genes that were mutated revealed significant dif-
ferences between the hypermutated and the non-hypermutated
tumors, highlighting the marked differences in the biology and
development of these CRC subtypes. ACVR2A (63 %), APC
(51 %), TGFBR2 (51 %), BRAF (40 %), MSH3 (40 %), and
MSH6 were the most frequently mutated genes in the
hypermutated tumors, whereas APC (81 %), TP53 (60 %),
KRAS (43 %), TTN (31%), and PIK3CA (18%) were the most
frequent targets of mutations in non-hypermutated tumors.
The RAS-MAPK, PI3K, and TGF-β signaling pathways were
altered in 80 vs. 59 % (hypermutated vs. non-hypermutated),
53 vs. 50 %, and 87 vs. 27 %, respectively, but little is still
known about which of these alterations are indeed necessary
for continued disease progression. Despite these differences,
95% of all tumors had a deregulatedWNTsignaling pathway,
predominantly due to mutations in APC, and nearly all tumors
had changes in MYC transcriptional targets, emphasizing the
critical role of these features in CRC [69••]. Recent work
demonstrated that APC inactivation is strictly required for
CRC maintenance, even in the presence of additional CRC-
associated oncogenic mutations in KRAS and TP53. In an
shRNA-based transgenic mouse model, restoration of endog-
enous Apc protein induced a rapid and sustained tumor regres-
sion and re-established tissue homeostasis. These results sug-
gest that small molecules that modulate the WNT pathway
could be clinically active for patients with APC-mutated
CRC [70]. Furthermore, Wiegering et al. described that
inhibition of MYC mRNA translation using silvestrol, a
compound that directly inhibits eIF4A in the translation
complex of MYC, suppresses tumor growth in a mouse
model of colorectal tumorigenesis [71]. Small molecules
that modulate the WNT pathway or target MYC-
translation initiation could therefore have clinical poten-
tial for patients with CRC.
Besides genetic changes, epigenetic alterations play a ma-
jor role in the development of CRC. Hinoue and colleagues
identified four DNA-methylation-based subgroups using a
genome-scale DNA methylation profiling. A CIMP-high
(CIMP-H) subgroup with an exceptionally high frequency of
cancer-specific hypermethylation. A CIMP-low (CIMP-L)
subgroup characterized by hypermethylation of a subset of
CIMP-H associated markers. And two non-CIMP subgroups,
one with a significantly higher frequency of TP53 mutations
and one with a marked low frequency of both cancer-specific
DNA hypermethylation and genemutations. Moreover,KRAS
mutations occurred within each of these subgroups, indicating
that not every KRAS mutant colorectal tumor has the same
DNA methylation profile and that KRASm CRC is probably
not a homogeneous group of patients who will respond simi-
larly to therapy [72].
Moreover, Popovici et al. demonstrated that a subgroup of
patients with BRAF wild-type stage II/III colon cancer have a
similar phenotype as patients with BRAFmutant colon cancer,
based on a high-sensitivity gene expression signature. Over
20 % of patients that were BRAFwild-type could be classified
as being BRAFm-like according to this signature, showing
clinicopathologic features similar to BRAFm patients, includ-
ing higher frequencies of mucinous histology, MSI and poor
overall survival and survival after relapse. As the majority of
these BRAFm-like patients harbored KRAS mutations, this
suggests a joint underlying biology between these KRASm
tumors, but it also indicates histologic and prognostic hetero-
geneity within the KRASm subpopulation [73]. In addition,
Tian and colleagues developed gene expression profiles that
characterized KRAS-, BRAF-, and PIK3CA-activated stage
II/III tumors, and they showed that tumors without mutations
in either of these genes could have a similar gene expression
profile [74]. This research indicates that mechanisms other
than oncogenic mutations can cause a similar pathway activa-
tion that can be identified by a similar transcriptional pattern.
More specifically, 79 of the 206 investigated tumors that had
no oncogenic mutation in either KRAS, BRAF, or PIK3CA
were classified as oncogenic based on their gene expression
profiles. This indicates that a significant part of the KRAS,
BRAF, and PIK3CAwild-type tumors share the same pheno-
type of an activated MAPK or PI3K pathway as those tumors
with at least one activating mutation. Indeed, the combined
oncogenic pathway signature was highly predictive for re-
sponse to EGFR-inhibitor therapy with better performance
than each of the three single mutation signatures and using
KRAS mutation status alone [74]. Furthermore, as this signa-
ture detects patients whose tumors have an activated MAPK
or PI3K pathway in the absence of genetic mutations, it may
also be useful to select patients for treatment with small mol-
ecule inhibitors directed against non-mutated BRAF, MEK,
PI3K, mTOR, or combinations of these agents [74].
However, paradoxical effects, such as seen with BRAF-
inhibitors in non-BRAFm cells may be a concern of such
strategy [75].
Subsequently, several research groups applied unsuper-
vised clustering methods to genome-wide expression data in
order to discover intrinsic molecular subtypes of CRC. De
Sousa et al. for instance described three molecularly distinct
CRC subtypes, the two well-known CIN and MSI tumors,
called colon cancer subtype (CCS) 1 and 2, and a third sub-
type (CCS3) that is largely microsatellite-stable containing
relatively more CpG-island methylator phenotype-positive tu-
mors but cannot be identified on the basis of genetic muta-
tions. KRAS mutations occurred in all the subgroups and
BRAF mutations occurred in both CCS2 and CCS3, again
indicating that KRAS and BRAF mutant CRC is not a
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homogeneous group and can be further differentiated into
multiple biological groups with potential clinical differences
in both prognosis and response to therapy. In fact, there was a
marked difference in response between the three subtypes to
cetuximab therapy in vitro, in xenografts, and in a clinical
setting where patients with CCS3-classified tumors were re-
sistant to cetuximab independently of KRAS mutation status
[76•]. Others identified similar or slightly different subtypes
which ranged in number from three to six, but there was a
clear overlap in key clinical and molecular features between
the subtypes from different research groups. Particularly, all
groups concurred on the identification of a highly aggressive
CRC subtype characterized by the expression of stem-cell
genes, epithelial-to-mesenchymal transition (EMT), and poor
prognosis [76•, 77•, 78•, 79•, 80•, 81•]. Therefore, the
Colorectal Cancer Subtyping Consortium (CRCSC) was
formed to reconcile data from six different research groups
who subsequently established four consensus subtypes called
CMS1-4. Although CMS1 was enriched for mutant BRAF
status, BRAF mutations did also occur in CMS3, CMS4, and
the unclassified subgroup. KRAS mutations were found in the
largest proportion of CMS-3 tumors, but frequently in all other
subtypes as well [82].
Taken together, all subtyping studies illustrate heterogene-
ity within the most common driver mutations, KRAS and
BRAF, indicating important differences in prognosis and re-
sponse to therapy with anti-EGFR agents and to a lesser ex-
tend to FOLFIRI treatment. Clearly, gene mutation status
alone is not enough to define the complexity of the underlying
biology of colorectal tumors. Therefore, to improve personal-
ized treatment of CRC patients, a more comprehensive anal-
ysis is needed, which is less likely to be influenced by inter-
and intra-tumor heterogeneity. CRC subtypes based on gene
expression profiles may represent the initial step towards a
better definition of CRC at the molecular level, but their prog-
nostic and predictive value remains to be elucidated and pro-
spectively validated.
Clinical Implications
The major challenge now is to translate this emerging knowl-
edge into a robust and reproducible classification system for
CRC that integrates tumor biology, pathology, and clinical
characteristics, and connect these subtypes to prognosis and
response to therapy. Genome-wide expression data already
provided initial evidence that particular drugs are more likely
to be effective in specific colorectal cancer subtypes. As men-
tioned previously, tumors belonging to the CCS3 subtype as
described by De Sousa et al., or the combined oncogenic ac-
tivated pathway signature as described by Tian et al., are un-
likely to respond to anti-EGFR directed treatment. In addition,
Sadanandam and colleagues described a further subdivision of
one CRC subtype representing patients with strong anti-
EGFR response [80•]. Other favorable outcomes were report-
ed in the metastatic setting for c-MET inhibitors in the
cetuximab-resistant transit amplifying (CR-TA) subtype and
for FOLFIRI in the stem-like subtype [80•].
One subgroup of CRC that was identified in each
subtyping study was the mesenchymal phenotype, character-
ized by worst clinical outcome, resistance to adjuvant chemo-
therapy, and elevated transforming growth factor-β (TGF-β)
signaling, a well-established feature in the induction of
epithelial-to-mesenchymal transition (EMT). Inhibition of
the TGF-β pathway may revert the mesenchymal tumors into
a more epithelial-like phenotype, making these tumors more
susceptible to chemotherapy [79•, 83]. This provides rationale
to combine chemotherapy with TGF-β receptor inhibitors in
patients with CRC harboring a mesenchymal phenotype as
identified by the CMS4 subtype according to the CRCSC. In
addition, Calon et al found that all mesenchymal poor prog-
nosis subtypes identified by the above-described studies rely
on genes expressed by stromal components, cancer-associated
fibroblasts (CAFs), rather than by epithelial cancer cells.
TGF-β signaling induces this CAF gene program, which
boosts the metastatic potential and the ability to regenerate
the malignant disease after therapy [56, 57, 84].
Pharmacological inhibition of TGF-β receptor 1 in the tumor
microenvironment using TGF-βR1-specific inhibitor
LY2157299 prevented metastasis formation and disease pro-
gression in patient-derived tumor organoids, which further
warrants investigating TGF-β inhibition in patients with
poor-prognosis CRC [57].
As previously mentioned, the genomic complexity of CRC
limits the efficacy of targeted therapies. However, high muta-
tional load may as well serve as a positive feature given the
fact that somatic mutations found in tumors can be recognized
by the patient’s own immune system due to their potential to
encode non-self immunogenic antigens [85]. Nonetheless, in
many tumors, the cytotoxic immune response is repressed by
negative feedback systems, such as the programmed death 1
(PD-1) pathway. Inhibition of PD-1 or its ligand has demon-
strated impressive clinical benefit in different types of cancer.
Since colorectal cancers with deficient MMR are character-
ized by a hypermutated phenotype and contain lymphocyte
infiltrates, it was hypothesized that especially dMMR tumors
are responsive to inhibition of the PD-1 pathway [86, 87•]. A
recently published phase II study indeed demonstrated that
patients with dMMR CRC are much more responsive to
anti-PD-1 immune checkpoint inhibitor pembrolizumab, than
are MMR proficient CRC patients, indicated by objective re-
sponse rates of 40 versus 0 %, respectively, and significantly
prolonged progression-free survival and overall survival times
[87•]. These impressive results strongly argue for clinical
studies investigating anti-PD-1 antibodies in patients with
MSI-like CRC as this gene expression classifier identifies an
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additional 10 % of CRC patients that harbor hypermutated
tumors, adding up to an approximate 25 % of all patients with
CRC who could potentially benefit from this novel treatment
strategy.
Conclusions and Future Perspectives
We begin to understand the heterogeneous character of CRC
and its impact on prognosis and response to therapy. To opti-
mize personalized therapy for patients with CRC, we should
focus on new patient selection strategies based on this increased
understanding of the underlying biology of the disease. In the
metastatic setting, physicians should already expand their mu-
tational analysis beyond KRAS (exon 2), as patients harboring
other KRAS or NRAS mutations are unlikely to respond to
EGFR inhibitors as well. The predictive role of BRAF muta-
tions for response to anti-EGFR treatment remains inconclu-
sive. Nevertheless, genomically driven clinical trials provide
promising treatment strategies for patients who may not be
eligible for anti-EGFR therapy (e.g., BRAFm and KRASm
patients). Emerging molecularly defined CRC subtypes based
on gene expression patterns highlight the heterogeneity beyond
genetic mutations and the lack of unique driver mutations in
each of these subtypes indicates distinct differences within the
KRASm and BRAFm populations. Clearly, genetic aberrations
are often not accurately defining a colorectal tumor’s phenotype
and are highly insufficient to guide treatment decisions in most
cases. In fact, thus far only one single-gene guided approach
has obtained proof of principle in the clinic, namely combined
BRAF and EGFR inhibition in BRAFm patients. Even in these
successful initial studies, patients respond very differently.
Therefore, validation of gene expression signatures, or equiva-
lent simpler marker systems, and implementing these in the
stratification of patients receiving pharmacological therapy
may help defining the patient population most likely to benefit
from a given (experimental) therapy. Furthermore, novel ther-
apeutic strategies should be investigated beyond the currently
used targets and drugs for CRC. Given the distinct differences
betweenmolecular CRC subtypes, vulnerability screens on rep-
resentative cell lines for each subtype, rather than on cell line
panels that contain multiple subtypes chosen on the basis of
single genetic mutations may be useful to this purpose [88,
89]. Ultimately, this updated and improved treatment individu-
alization based on comprehensive analysis of a patient’s tumor
should enable physicians to make rational treatment decisions
for each individual CRC patient.
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